Phenoxybenzamine HCl Clinical Trials

Size	Price	Qty
50mg	USD 97
1g	USD 670

Clinical Trials

Multiple clinical trials evaluate Phenoxybenzamine HCl across Phase 2, Phase 3, and Phase 4 development for conditions such as pheochromocytoma, paraganglioma, congenital heart disease, and perioperative management during cardiac surgery. Sponsored predominantly by academic institutions and university medical centers, these investigations span completed, actively recruiting, and terminated or withdrawn protocols assessing preoperative alpha-adrenergic blockade and pediatric parenteral applications. Overall, these studies focus on evaluating hemodynamic stability and the comparative efficacy of adrenoceptor inhibition in surgical settings.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05702944	RECRUITING	Pheochromocytoma; Paraganglioma; Adrenalectomy; Status; Adrenergics Causing Adverse Effects in Therapeutic Use	Seoul National University Hospital	2023-01-18	PHASE4
NCT03176693	COMPLETED	Pheochromocytoma; Paraganglioma	University of California, Los Angeles	2017-05-05	PHASE3
NCT01379898	COMPLETED	Pheochromocytoma	University Medical Center Groningen	2011-12	PHASE4
NCT01379898	Completed	Pheochromocytoma	University Medical Center Groningen\|Radboud University Medical Center\|UMC Utrecht\|VU University of Amsterdam\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Leiden University Medical Center\|Erasmus Medical Center\|Maastricht University Medical Center\|St. Antonius Hospital\|Medisch Spectrum Twente\|Maxima Medical Center\|Canisius-Wilhelmina Hospital\|Onze Lieve Vrouwe Gasthuis\|Atrium Medical Center\|Isala	2011-12	Phase 4
NCT00770705	WITHDRAWN	Congenital Heart Disease	Vanderbilt University	2008-10	PHASE2
NCT00569855	COMPLETED	Open-heart Surgery; Cardiopulmonary Bypass	University of Arkansas	2001-02	PHASE2
NCT00620945	TERMINATED	Congenital Heart Surgery; Cardiopulmonary Bypass	The Cleveland Clinic	2006-06
NCT00770705	Withdrawn	Congenital Heart Disease	Vanderbilt University\|Vanderbilt University Medical Center	2008-10	Phase 2

(data from https://clinicaltrials.gov, updated on 2025-06-12)

Check the Phenoxybenzamine HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Phenoxybenzamine HCl acts as a non-specific, irreversible alpha-adrenergic antagonist by forming permanent covalent bonds with alpha adrenoceptors, thereby blocking endogenous catecholamines such as adrenaline and noradrenaline from binding. This receptor blockade inhibits vascular smooth muscle constriction to induce pronounced vasodilation, directly addressing hypertension and restoring hemodynamic balance in clinical settings such as pheochromocytoma and perioperative surgical management.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).